NLS Pharmaceutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for NLS Pharmaceutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 23.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 29 Jul 2024 |
Recent future growth updates
Recent updates
NLS Pharmaceutics gets delisting determination letter from Nasdaq
Oct 05NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate
Sep 27NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders
Jul 28Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation
Mar 04
Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky
Nov 12In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NLS Pharmaceutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | N/A | -2 | N/A | N/A | 1 |
| 6/30/2024 | N/A | -7 | -4 | -4 | N/A |
| 3/31/2024 | N/A | -9 | -7 | -7 | N/A |
| 12/31/2023 | N/A | -12 | -10 | -10 | N/A |
| 9/30/2023 | N/A | -14 | -12 | -12 | N/A |
| 6/30/2023 | N/A | -15 | -14 | -14 | N/A |
| 3/31/2023 | N/A | -16 | -14 | -14 | N/A |
| 12/31/2022 | N/A | -16 | -14 | -14 | N/A |
| 9/30/2022 | N/A | -16 | -13 | -13 | N/A |
| 6/30/2022 | N/A | -16 | -13 | -13 | N/A |
| 3/31/2022 | N/A | -14 | -14 | -14 | N/A |
| 12/31/2021 | N/A | -12 | -15 | -15 | N/A |
| 9/30/2021 | N/A | -9 | N/A | N/A | N/A |
| 6/30/2021 | N/A | -6 | -10 | -10 | N/A |
| 3/31/2021 | N/A | -5 | -5 | -5 | N/A |
| 12/31/2020 | N/A | -3 | -1 | -1 | N/A |
| 9/30/2020 | N/A | -3 | N/A | N/A | N/A |
| 6/30/2020 | N/A | -3 | -1 | -1 | N/A |
| 3/31/2020 | N/A | -4 | -1 | -1 | N/A |
| 12/31/2019 | N/A | -5 | 0 | 0 | N/A |
| 9/30/2019 | N/A | -6 | N/A | N/A | N/A |
| 6/30/2019 | N/A | -6 | 0 | 0 | N/A |
| 3/31/2019 | N/A | -6 | -2 | -2 | N/A |
| 12/31/2018 | N/A | -5 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if NLSP's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if NLSP's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if NLSP's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if NLSP's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if NLSP's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NLSP's Return on Equity is forecast to be high in 3 years time